Financhill
Buy
70

TAK Quote, Financials, Valuation and Earnings

Last price:
$15.58
Seasonality move :
4.51%
Day range:
$15.52 - $15.62
52-week range:
$12.80 - $15.69
Dividend yield:
4.24%
P/E ratio:
197.72x
P/S ratio:
1.68x
P/B ratio:
1.02x
Volume:
1.3M
Avg. volume:
2.9M
1-year change:
18.3%
Market cap:
$49.2B
Revenue:
$30.1B
EPS (TTM):
$0.08

TAK Analysts' Consensus Rating

The 3 analysts providing 12-month price projections for Takeda Pharmaceutical Co., Ltd. shares anticipate an average target of $17.93, ranging from a low estimate of $16.98 to a high estimate of $18.82. This average target implies a growth of 14.94% compared to the current stock price of $15.58.

Consensus Price Target

$17.93

Highest Price Target

$18.82

Lowest Price Target

$16.98

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Analyst Ratings

6M Ago 1M Ago Current
Buy 3 3 3

Hold 1 0 0

Sell 0 0 0
Consensus Buy Buy Buy

TAK Recommendation Trends

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is DocuSign Stock Undervalued?
Is DocuSign Stock Undervalued?

Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…

Is SentinelOne Stock Undervalued?
Is SentinelOne Stock Undervalued?

Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…

Is Broadcom Stock on Sale?
Is Broadcom Stock on Sale?

Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…

Stock Ideas

Buy
57
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 64x

Buy
55
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 37x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Buy
80
TVTX alert for Dec 25

Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.

Buy
68
KOD alert for Dec 25

Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.

Buy
64
ZCSH alert for Dec 25

Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock